|
|
Post by kite on Jun 13, 2020 11:02:10 GMT -5
www.globenewswire.com/news-release/2020/06/13/2047727/0/en/Investigator-Initiated-Study-Shows-Switching-to-Afrezza-Improves-Glucose-Control-with-No-Additional-Hypoglycemia-in-T2DM.html WESTLAKE VILLAGE, Calif., June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza® (insulin human) Inhalation Powder will be presented at the American Diabetes Association’s 80th Scientific Sessions during the ePoster session (Poster 990) on Saturday, June 13, 2020. The lead author, Mark Kipnes, MD (Diabetes and Glandular Disease Clinic, San Antonio, Texas) presented clinical data from an investigator-initiated observational “switch” study that evaluated quality of life and glucose control in patients with type 2 diabetes previously treated with injected mealtime insulin. Following conversion to Afrezza, patients were followed for 14 weeks, and glucose control (measured by both A1C and glucose time in range), rates of hypoglycemia and quality of life were assessed. Study subjects experienced a significant (0.8%) reduction in A1C levels at the end of the 14-week treatment period after switching from their injected mealtime insulin to Afrezza. Subjects maintained 66-69% “time in range” (time with glucose values in the range of 70-180 mg/dL) and reduced the time spent with glucose <90 mg/dL. Afrezza therapy resulted in a significant improvement in diabetes quality of life scores. “This study shows that Afrezza treatment—combined with the use of continuous glucose monitoring—can improve overall glucose control while maintaining time in range. Importantly, the study also demonstrates a reduction in blood glucose levels without additional hypoglycemia,” stated Dr. Kipnes. “In addition, after switching to Afrezza, these individuals reported an improvement in quality of life measures. This study demonstrates that by rapidly adjusting Afrezza doses, improved clinical outcomes were possible, and patients reported less burden from their diabetes treatment.” MannKind provided financial support and study product for use in this study.
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Jun 13, 2020 13:47:22 GMT -5
You beat me to it, Kite. I was just going to post this.
It's nice to start seeing the good things that will be coming to the ADA.
|
|
|
|
Post by omeshrin on Jun 13, 2020 17:43:03 GMT -5
I just hope that the data will get the ball rolling. I wonder, will the naysayers and those who were quiet before start to be more open and vocal about this treatment option, knowing that it could benefit so many people? Or will they say "yes, it's good, but I won't do anything about it and leave it in the hands of fate."
In this legal climate, I could understand if it went both ways. Everyone seems to be trying to cover their butt, unless their interests lie in helping people get the right treatments. But once peds trial goes well and as we see more data, I find fewer and fewer legitimate excuses for clinicians and regulators to keep silent on these issues and not take an interest.
Edit: Having said that, I am happy of course but also completely not surprised about these results. I feel like a lawyer at a trial in which I already sort of know what the result will be, but just annoyed at all the bureaucracy. : )
|
|
|
|
Post by hellodolly on Jun 14, 2020 8:50:08 GMT -5
www.globenewswire.com/news-release/2020/06/13/2047727/0/en/Investigator-Initiated-Study-Shows-Switching-to-Afrezza-Improves-Glucose-Control-with-No-Additional-Hypoglycemia-in-T2DM.html WESTLAKE VILLAGE, Calif., June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza® (insulin human) Inhalation Powder will be presented at the American Diabetes Association’s 80th Scientific Sessions during the ePoster session (Poster 990) on Saturday, June 13, 2020. The lead author, Mark Kipnes, MD (Diabetes and Glandular Disease Clinic, San Antonio, Texas) presented clinical data from an investigator-initiated observational “switch” study that evaluated quality of life and glucose control in patients with type 2 diabetes previously treated with injected mealtime insulin. Following conversion to Afrezza, patients were followed for 14 weeks, and glucose control (measured by both A1C and glucose time in range), rates of hypoglycemia and quality of life were assessed. Study subjects experienced a significant (0.8%) reduction in A1C levels at the end of the 14-week treatment period after switching from their injected mealtime insulin to Afrezza. Subjects maintained 66-69% “time in range” (time with glucose values in the range of 70-180 mg/dL) and reduced the time spent with glucose <90 mg/dL. Afrezza therapy resulted in a significant improvement in diabetes quality of life scores. “This study shows that Afrezza treatment—combined with the use of continuous glucose monitoring—can improve overall glucose control while maintaining time in range. Importantly, the study also demonstrates a reduction in blood glucose levels without additional hypoglycemia,” stated Dr. Kipnes. “In addition, after switching to Afrezza, these individuals reported an improvement in quality of life measures. This study demonstrates that by rapidly adjusting Afrezza doses, improved clinical outcomes were possible, and patients reported less burden from their diabetes treatment.”MannKind provided financial support and study product for use in this study. People will show up and pretend they know more than the lead on this trial or dispute what ws said with one other red herring. Watch....wait.....reveal yourselves..... |
|
|
|
Post by boytroy88 on Jun 14, 2020 18:03:10 GMT -5
Wonder if this will move the needle tomorrow. Wish this came out tomorrow morning at 6am PST instead.
|
|
|
|
Post by alethea on Jun 15, 2020 12:58:15 GMT -5
www.globenewswire.com/news-release/2020/06/13/2047727/0/en/Investigator-Initiated-Study-Shows-Switching-to-Afrezza-Improves-Glucose-Control-with-No-Additional-Hypoglycemia-in-T2DM.html WESTLAKE VILLAGE, Calif., June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza® (insulin human) Inhalation Powder will be presented at the American Diabetes Association’s 80th Scientific Sessions during the ePoster session (Poster 990) on Saturday, June 13, 2020. The lead author, Mark Kipnes, MD (Diabetes and Glandular Disease Clinic, San Antonio, Texas) presented clinical data from an investigator-initiated observational “switch” study that evaluated quality of life and glucose control in patients with type 2 diabetes previously treated with injected mealtime insulin. Following conversion to Afrezza, patients were followed for 14 weeks, and glucose control (measured by both A1C and glucose time in range), rates of hypoglycemia and quality of life were assessed. Study subjects experienced a significant (0.8%) reduction in A1C levels at the end of the 14-week treatment period after switching from their injected mealtime insulin to Afrezza. Subjects maintained 66-69% “time in range” (time with glucose values in the range of 70-180 mg/dL) and reduced the time spent with glucose <90 mg/dL. Afrezza therapy resulted in a significant improvement in diabetes quality of life scores. “This study shows that Afrezza treatment—combined with the use of continuous glucose monitoring—can improve overall glucose control while maintaining time in range. Importantly, the study also demonstrates a reduction in blood glucose levels without additional hypoglycemia,” stated Dr. Kipnes. “In addition, after switching to Afrezza, these individuals reported an improvement in quality of life measures. This study demonstrates that by rapidly adjusting Afrezza doses, improved clinical outcomes were possible, and patients reported less burden from their diabetes treatment.”MannKind provided financial support and study product for use in this study. People will show up and pretend they know more than the lead on this trial or dispute what ws said with one other red herring. Watch....wait.....reveal yourselves..... Yeah. I can't wait for the remaining duo of nattering nabobs of negativism to start dumping all kinds of crap on the study data. Keep in mind that these are the guys that say MNKD stock price is NOT manipulated. They have an agenda and it ain't positive. |
|
|
|
Post by rfogel on Jun 15, 2020 14:27:49 GMT -5
Were the subjects using CGMs before being switched to afrezza?
|
|
|
|
Post by sayhey24 on Jun 15, 2020 15:10:25 GMT -5
Were the subjects using CGMs before being switched to afrezza? The only way to get the baseline TIR with the RAA was with CGMs. |
|
